Immune Checkpoint Blockade in Gastrointestinal Cancers: The Current Status and Emerging Paradigms.
Clinical trials
combination strategies
gastrointestinal cancers
immune checkpoint inhibitors
primary resistance
Journal
Journal of immunotherapy and precision oncology
ISSN: 2590-017X
Titre abrégé: J Immunother Precis Oncol
Pays: United States
ID NLM: 101768397
Informations de publication
Date de publication:
Feb 2020
Feb 2020
Historique:
received:
04
10
2019
revised:
20
12
2019
accepted:
26
12
2019
entrez:
27
6
2022
pubmed:
10
2
2020
medline:
10
2
2020
Statut:
epublish
Résumé
Immunotherapy is a rapidly evolving treatment paradigm that holds promise to provide long-lasting survival benefits for patients with cancer. This promise, however, remains unfulfilled for the majority of patients with gastrointestinal (GI) cancers, as significant limitations in efficacy exist with immune checkpoint inhibitors (ICIs) in this disease group. A plethora of novel combination treatment strategies are currently being investigated in various clinical trials to make them more efficacious as our understanding of molecular mechanisms mediating resistance to immunotherapy advances. In this article, we summarize the current status of immune checkpoint blockade in GI cancers and discuss the biological rationales that underlie the emerging treatment strategies being tested in ongoing clinical trials in combination with ICIs. We also highlight the promising early results from these strategies and provide future perspectives on enhancing response to immunotherapy for patients with GI cancers.
Identifiants
pubmed: 35756177
doi: 10.4103/JIPO.JIPO_1_20
pmc: PMC9208391
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
3-15Informations de copyright
© 2020 Journal of Immunotherapy and Precision Oncology | Published by Wolters Kluwer - Medknow.
Déclaration de conflit d'intérêts
Conflicts of interest The authors disclosed no conflicts of interest related to this article.
Références
N Engl J Med. 2015 Jun 25;372(26):2509-20
pubmed: 26028255
Bone Marrow Transplant. 2000 May;25 Suppl 2:S88-95
pubmed: 10933198
Gastroenterology. 2010 Apr;138(4):1374-83
pubmed: 20004201
Cancer Discov. 2018 Sep;8(9):1156-1175
pubmed: 30012853
Transl Lung Cancer Res. 2018 Sep;7(Suppl 3):S198-S201
pubmed: 30393600
Nat Med. 2018 Mar;24(3):262-270
pubmed: 29431745
Cancer Cell. 2011 Jun 14;19(6):715-27
pubmed: 21665146
Mol Ther. 2017 May 3;25(5):1248-1258
pubmed: 28366766
Proc Natl Acad Sci U S A. 2012 Oct 23;109(43):17561-6
pubmed: 23045683
Semin Oncol. 2012 Jun;39(3):311-22
pubmed: 22595054
JAMA Oncol. 2019 Apr 01;5(4):546-550
pubmed: 30570649
F1000Res. 2018 Mar 14;7:316
pubmed: 29560265
Nat Med. 2015 Nov;21(11):1350-6
pubmed: 26457759
Nat Biotechnol. 2018 Sep;36(8):758-764
pubmed: 30010674
Oncotarget. 2017 Sep 12;8(56):95036-95037
pubmed: 29221108
Lancet. 2018 May 26;391(10135):2128-2139
pubmed: 29754777
Lancet. 2017 Jun 24;389(10088):2492-2502
pubmed: 28434648
Epigenomics. 2016 Mar;8(3):415-28
pubmed: 26950532
Trends Cancer. 2016 Feb 1;2(2):95-109
pubmed: 27014745
Nat Med. 2007 Nov;13(11):1299-307
pubmed: 17922010
Lancet Oncol. 2018 Jul;19(7):940-952
pubmed: 29875066
Immunity. 2016 Mar 15;44(3):609-621
pubmed: 26944201
Clin Cancer Res. 2019 Mar 1;25(5):1462-1471
pubmed: 30377198
Proc Natl Acad Sci U S A. 2018 Mar 6;115(10):2455-2460
pubmed: 29463725
Mol Cancer Res. 2006 May;4(5):339-49
pubmed: 16687489
Cell Death Dis. 2019 Mar 20;10(4):273
pubmed: 30894509
J Immunother Cancer. 2017 Jul 18;5(1):53
pubmed: 28716061
Angiogenesis. 2017 May;20(2):185-204
pubmed: 28361267
Science. 2005 Jan 7;307(5706):58-62
pubmed: 15637262
Cancer Sci. 2013 Aug;104(8):1112-9
pubmed: 23648122
Clin Exp Immunol. 2013 Jun;172(3):500-6
pubmed: 23600839
Front Immunol. 2018 Dec 21;9:3081
pubmed: 30627131
Oncotarget. 2017 Jan 31;8(5):8633-8647
pubmed: 28052009
Cell. 2006 Jan 27;124(2):263-6
pubmed: 16439202
Cancer Immunol Res. 2018 Dec;6(12):1561-1577
pubmed: 30341213
J Immunother Cancer. 2018 Aug 22;6(1):80
pubmed: 30134977
J Gastroenterol Hepatol. 2016 Jul;31(7):1246-56
pubmed: 26729006
Cancer Immunol Res. 2014 May;2(5):393-8
pubmed: 24795351
Cancer Res. 2014 Jun 1;74(11):2913-21
pubmed: 24840647
Am J Cancer Res. 2016 Nov 01;6(11):2514-2531
pubmed: 27904768
Immunology. 2013 Feb;138(2):105-15
pubmed: 23216602
J Clin Oncol. 2018 Jan 1;36(1):61-67
pubmed: 29116900
N Engl J Med. 2016 Dec 8;375(23):2255-2262
pubmed: 27959684
Ann Oncol. 2019 Jul 1;30(7):1134-1142
pubmed: 30918950
Mol Cancer. 2019 Mar 30;18(1):60
pubmed: 30925919
Front Pharmacol. 2017 Aug 24;8:575
pubmed: 28970798
J Clin Oncol. 2018 Mar 10;36(8):773-779
pubmed: 29355075
Science. 2014 May 9;344(6184):641-5
pubmed: 24812403
J Autoimmun. 2019 Jun;100:17-26
pubmed: 30862450
BMC Cancer. 2018 Dec 5;18(1):1220
pubmed: 30518340
Clin Cancer Res. 2004 Jun 1;10(11):3658-66
pubmed: 15173072
Int J Mol Sci. 2018 Nov 14;19(11):
pubmed: 30441809
Cancer Immunol Immunother. 2012 Apr;61(4):511-21
pubmed: 21971588
ESMO Open. 2018 Mar 15;3(3):e000326
pubmed: 29636988
Clin Cancer Res. 2016 Jul 1;22(13):3286-97
pubmed: 26861458
J Transl Med. 2015 Feb 01;13:47
pubmed: 25638150
Clin Cancer Res. 2018 Mar 15;24(6):1326-1336
pubmed: 29367431
Trends Cell Biol. 2019 Jan;29(1):31-43
pubmed: 30153961
Cancer Res. 2008 Feb 1;68(3):889-92
pubmed: 18245491
J Pers Med. 2019 Jan 16;9(1):
pubmed: 30654522
Proc Natl Acad Sci U S A. 2014 Aug 12;111(32):11774-9
pubmed: 25071169
Scand J Immunol. 1996 May;43(5):537-44
pubmed: 8633212
Clin Transl Immunology. 2017 Apr 07;6(4):e136
pubmed: 28523126
Cancer Res. 2018 Dec 15;78(24):6717-6725
pubmed: 30498083
Front Oncol. 2018 Mar 29;8:92
pubmed: 29651407
Cell. 2015 Aug 27;162(5):961-73
pubmed: 26317465
Oncologist. 2016 Oct;21(10):1200-1211
pubmed: 27412392
Genes Cancer. 2018 May;9(5-6):176-189
pubmed: 30603054
J Clin Oncol. 2020 Jun 20;38(18):2053-2061
pubmed: 32343640
Nature. 2016 Aug 4;536(7614):91-5
pubmed: 27350335
Lancet Oncol. 2017 Sep;18(9):1182-1191
pubmed: 28734759
Immunity. 2013 Jul 25;39(1):1-10
pubmed: 23890059
Cancer Discov. 2016 Oct;6(10):1090-1105
pubmed: 27655435
Ann Oncol. 2018 Apr 1;29(4):1030-1036
pubmed: 29360924
Cancer Res. 2019 Jan 15;79(2):311-319
pubmed: 30482774
PLoS One. 2016 Oct 25;11(10):e0164514
pubmed: 27780254
JAMA Oncol. 2018 May 10;4(5):e180013
pubmed: 29543932
Cancer Immunol Res. 2017 Sep;5(9):790-803
pubmed: 28775208
Science. 2017 Jul 28;357(6349):409-413
pubmed: 28596308
Trends Cancer. 2018 Mar;4(3):239-255
pubmed: 29506673
Nat Genet. 2019 Feb;51(2):202-206
pubmed: 30643254
Lancet Oncol. 2019 Jun;20(6):849-861
pubmed: 31003911
Clin Epigenetics. 2017 May 30;9:59
pubmed: 28572863
Hum Vaccin Immunother. 2018 Apr 3;14(4):839-846
pubmed: 29420123